Related Experiment Video
Updated: May 6, 2026
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
[Anti-tumor efficacy of P53 with 9R cell-penetrating peptides]
Yuan Liu1, Rui Chen, Nan Zhang
1Biopharmaceutical Teaching and Research Section, College of Life Science, Northeast Agricultural University, Harbin 150030, Heilongjiang, China.
Abstract:
To enhance the penetration of P53 into tumor cells by fusion it with the cell penetrating peptide 9R. The fusion gene of 9R-p53 was cloned into the expression vector. The fusion protein, CPPs-P53, was expressed and purified. We detected the rate of cell growth inhibition and apoptosis by MTT and Annexin-V-FITC/PI double stained method respectively for measuring its effect on tumor cells. CPPs-P53 and P53 were successfully expressed and purified, the purity of both proteins reached up to 90%. MTT assay showed that the cell growth inhibition by CPPs-P53 was more efficient than P53, and the rate of cell growth inhibition is dose-dependent. The apoptosis experiment showed that P53 could induce apoptosis of tumor cells. Compared with the P53, CPPs-P53 had a more significant effect in inducing cell apoptosis (**P < 0.01). The CPPs-P53 shows more significant effects than P53 in inhibiting cell growth and inducing apoptosis on tumor cells.
Insights
This study fused the tumor suppressor P53 with the cell-penetrating peptide 9R, creating CPPs-P53. CPPs-P53 demonstrated superior tumor cell growth inhibition and apoptosis induction compared to P53 alone.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- The tumor suppressor protein P53 plays a critical role in preventing cancer.
- Effective delivery of P53 into tumor cells remains a challenge for cancer therapy.
- Cell-penetrating peptides (CPPs) offer a potential solution for enhancing intracellular delivery.
Purpose of the Study:
- To enhance the tumor cell penetration of P53 by fusing it with the cell-penetrating peptide 9R.
- To evaluate the efficacy of the resulting fusion protein, CPPs-P53, in inhibiting tumor cell growth and inducing apoptosis.
- To compare the therapeutic effects of CPPs-P53 with native P53.
Main Methods:
- A fusion gene (9R-p53) was constructed and cloned into an expression vector.
- The fusion protein CPPs-P53 was expressed and purified to high purity (>90%).
- Cell growth inhibition was assessed using MTT assays, and apoptosis was measured by Annexin-V-FITC/PI double staining.
Main Results:
- Both P53 and CPPs-P53 were successfully expressed and purified with high purity.
- CPPs-P53 exhibited significantly more efficient dose-dependent inhibition of tumor cell growth compared to P53.
- CPPs-P53 demonstrated a more potent induction of tumor cell apoptosis than P53 (P < 0.01).
Conclusions:
- Fusion of P53 with the 9R peptide enhances its intracellular delivery and therapeutic potential.
- CPPs-P53 is a promising candidate for cancer therapy due to its enhanced ability to inhibit tumor cell growth and induce apoptosis.
- This strategy offers a novel approach for improving the efficacy of P53-based cancer treatments.
